Choate Investment Advisors’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Choate Investment Advisors’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,128	Closed	-$62K	–	360
2023 Q1	$62K	Hold	5,128	–	–	﹤0.01%	289
2022 Q4	$23.3K	Hold	5,128	–	–	﹤0.01%	317
2022 Q3	$34K	Hold	5,128	–	–	﹤0.01%	278
2022 Q2	$55K	Hold	5,128	–	–	﹤0.01%	288
2022 Q1	$98K	Hold	5,128	–	–	0.01%	309
2021 Q4	$184K	Hold	5,128	–	–	0.01%	282
2021 Q3	$377K	Buy	+5,128	New	+$395K	0.02%	198

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Choate Investment Advisors's SGTX Position: Q2 2023 in Review

Choate Investment Advisors sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2023, closing a stake of 5,128 shares — an estimated $62K sold.

Choate Investment Advisors first reported a position in SGTX in Q3 2021 and held it in 7 quarters. The position peaked at $377K in Q3 2021. 16 funds tracked by Wall St. Rank hold SGTX as of Q2 2023.

Choate Investment Advisors reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Choate Investment Advisors sold 5,128 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $62K.
Choate Investment Advisors first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q3 2021 and held it in 7 quarters.
Choate Investment Advisors's Sigilon Therapeutics, Inc. Common Stock position peaked at $377K in Q3 2021.
16 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Choate Investment Advisors's 13F filing for Q2 2023, filed 1 Aug 2023.